Abstract:The sesquiterpene lactone artemisinin from Artemisia annua L. is well established for malaria therapy, but its bioactivity spectrum is much broader. In this review, we give a comprehensive and timely overview of the literature regarding the immunosuppressive activity of artemisinin-type compounds toward inflammatory and autoimmune diseases. Numerous receptor-coupled signaling pathways are inhibited by artemisinins, including the receptors for interleukin-1 (IL-1), tumor necrosis factor-α (TNF-α), β3-integrin, or RANKL, toll-like receptors and growth factor receptors. Among the receptor-coupled signal transducers are extracellular signal-regulated protein kinase (ERK), c-Jun N-terminal kinase (JNK), phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K), AKT serine/threonine kinase (AKT), mitogen-activated protein kinase (MAPK)/extracellular signal regulated kinase (ERK) kinase (MEK), phospholipase C γ1 (PLCγ), and others. All these receptors and signal transduction molecules are known to contribute to the inhibition of the transcription factor nuclear factor κ B (NF-κB). Artemisinins may inhibit NF-κB by silencing these upstream pathways and/or by direct binding to NF-κB. Numerous NF-κB-regulated downstream genes are downregulated by artemisinin and its derivatives, for example, cytokines, chemokines, and immune receptors, which regulate immune cell differentiation, apoptosis genes, proliferation-regulating genes, signal transducers, and genes involved in antioxidant stress response. In addition to the prominent role of NF-κB, other transcription factors are also inhibited by artemisinins (mammalian target of rapamycin [mTOR], activating protein 1 [AP1]/FBJ murine osteosarcoma viral oncogene homologue [FOS]/JUN oncogenic transcription factor [JUN]), hypoxia-induced factor 1α (HIF-1α), nuclear factor of activated T cells c1 (NF-ATC1), Signal transducers and activators of transcription (STAT), NF E2-related factor-2 (NRF-2), retinoic-acid-receptor-related orphan nuclear receptor γ (ROR-γt), and forkhead box P-3 (FOXP-3). Many in vivo experiments in disease-relevant animal models demonstrate therapeutic efficacy of artemisinin-type drugs against rheumatic diseases (rheumatoid arthritis, osteoarthritis, lupus erythematosus, arthrosis, and gout), lung diseases (asthma, acute lung injury, and pulmonary fibrosis), neurological diseases (autoimmune encephalitis, Alzheimer's disease, and myasthenia gravis), skin diseases (dermatitis, rosacea, and psoriasis), inflammatory bowel disease, and other inflammatory and autoimmune diseases. Randomized clinical trials should be conducted in the future to translate the plethora of preclinical results into clinical practice.

Artemisinin inhibits inflammatory response via regulating NF-κB and MAPK signaling pathways.

The Anti-Malarial Artemisinin Inhibits Pro-Inflammatory Cytokines Via the NF-ÎºB Canonical Signaling Pathway in PMA-induced THP-1 Monocytes

Artemisinin Attenuates Lipopolysaccharide-Stimulated Proinflammatory Responses By Inhibiting Nf-Kappa B Pathway In Microglia Cells

Anti-malarial drug: the emerging role of artemisinin and its derivatives in liver disease treatment

The immunosuppressive activity of artemisinin‐type drugs towards inflammatory and autoimmune diseases

Advances in the Study of Artemisinin and Its Derivatives for the Treatment of Rheumatic Skeletal Disorders, Autoimmune Inflammatory Diseases, and Autoimmune Disorders: a Comprehensive Review

Anti-inflammatory and immunoregulatory functions of artemisinin and its derivatives

Resolving Neuroinflammation, the Therapeutic Potential of the Anti-Malaria Drug Family of Artemisinin

Artemether attenuates LPS-induced inflammatory bone loss by inhibiting osteoclastogenesis and bone resorption via suppression of MAPK signaling pathway

Artemisinin suppresses sympathetic hyperinnervation following myocardial infarction via anti-inflammatory effects

Effects of Artemisinin on Acute Inflammation

Pre-clinical studies comparing the anti-inflammatory potential of artemisinic compounds by targeting NFκB/TNF-α/NLRP3 and Nrf2/TRX pathways in Balb/C mice

Artesunate inhibits LPS-induced production of TNF-α via inhibition of NF-κB signal pathway in human rheumatoid arthritis fibroblast-like synoviocytes

Artemisinin Protects Porcine Mammary Epithelial Cells Against Lipopolysaccharide-Induced Inflammatory Injury by Regulating the NF-κB and MAPK Signaling Pathways.

Artemisinin inhibits tumor lymphangiogenesis by suppression of vascular endothelial growth factor C.

TPN10466 ameliorates Concanavalin A-induced autoimmune hepatitis in mice via inhibiting ERK/JNK/p38 signaling pathway

Artemisinin Inhibits Extracellular Matrix Metalloproteinase Inducer (EMMPRIN) and Matrix Metalloproteinase‐9 Expression Via a Protein Kinase Cδ/p38/extracellular Signal‐regulated Kinase Pathway in Phorbol Myristate Acetate‐induced THP‐1 Macrophages

Therapeutic Potential of Artemisinin and Its Derivatives in Managing Kidney Diseases

Dihydroartemisinin regulates the immune system by promotion of CD8+ T lymphocytes and suppression of B cell responses

Artemisinin and deoxyartemisinin isolated from Artemisia annua L. promote distinct antinociceptive and anti-inflammatory effects in an animal model

Artemisinin Inhibits Monocyte Adhesion to HUVECs Through the NF-κB and MAPK Pathways in Vitro.